Recently, Thermo Fisher Scientific sat down with Dr. Carolina Felix, Senior Biomedical Scientist at the Liverpool Clinical Laboratories (LCL) Molecular Pathology Service, to learn about her lab’s experience working with Thermo Fisher’s Service and Support team for a research assay validation consultation ..read more

Some NGS runs on her Ion GeneStudio S5 System had a high number of low-quality reads, and she didn't know why ..read more

Thermo Fisher Scientific has announced the recipients of the latest Oncomine Clinical Research Grant. This grant program supports investigator-initiated studies in oncology, with a focus on molecular profiling and the democratization of precision medicine ..read more

A recently published article by the BLOODPAC Consortium details the potential of liquid biopsy in the management of cancer and highlights the barriers to adoption, particularly in underserved populations.  ..read more

The theme of the 35th European Congress of Pathology (ECP) “Pathology – a bridge between science and medicine” was prominently evident throughout the renowned congress for the latest pathology updates in Europe ..read more

Precision medicine is on the rise. However, these groundbreaking, targeted therapies for hard-to-treat diseases like cancer can only help improve patient outcomes if rapid genomic testing is accessible and can quickly inform care decisions.  ..read more

Precision medicine is rapidly changing our understanding of cancer research and treatment decisions. These breakthrough, personalized treatments hold promise even for patients with historically hard-to-treat diseases, like lung or breast cancer. But expanding the benefits of precision medicine to more patients also means expanding the global reach of next-generation sequencing (NGS)-based testing, which helps connect patients to tailored treatments. To help expand our understanding of precision medicine in oncology and the importance of rapid, molecular testing, Thermo Fisher Scientific laun ..read more

Next-generation sequencing (NGS) has become an increasingly important tool for identifying molecular biomarkers that can help guide treatment decisions for cancer patients ..read more

In his recent talk at OncomineWorld 2023, Dr. Bekim Sadikovic presented a strong, evidence-based argument for frontline next-generation sequencing (NGS) in myeloid malignancy testing ..read more

  ..read more